HOPE Therapeutics, an interventional psychiatry network owned by NRx Pharmaceuticals (NRXP), announced the acquisition of a strategic interest in Cohen and Associates, and its incorporation into the HOPE Network. Additionally, Rebecca Cohen, MD has joined HOPE as Medical Director, overseeing medical standards of care throughout HOPE’s Florida locations. Cohen, LLC is one of the premier interventional Psychiatry clinics in the region. The clinic offers a full range of treatments for suicidal depression, PTSD and other CNS disorders, including ketamine, Transcranial Magnetic Stimulation, and medication management. Dr. Cohen is an Interventional Psychiatrist and Psychopharmacologist specializing in the treatment of mood and anxiety disorders as well as a nationally recognized expert in TMS.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRXP:
- NRx Pharmaceuticals (NASDAQ: NRXP) Pursues Dual Pathway for Preservative-Free Ketamine-Based Therapies
- VTI ETF Daily Update, 10/16/2025
- Positive Regulatory Environment and Strategic Alignment Boost Confidence in NRX Pharmaceuticals’ Buy Rating
- VTI ETF Daily Update, 10/14/2025
- VTI ETF Daily Update, 10/13/2025